首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献，搜索用时 15 毫秒
1.
Serum antibody titers to canine parvovirus (CPV), canine adenovirus-1 (CAV-1), and canine distemper virus (CDV) were measured in dogs with known immunization status. The dogs represented 3 groups: nonvaccinated dogs less than 12 months old; vaccinated dogs less than 12 months old; and adult dogs greater than 12 months old. For practical reasons, the population from which the specimens were obtained could be considered as free from natural infection with CAV-1 and CDV. In nonvaccinated dogs less than 12 months old, antibodies against all 3 viruses were measured at the time the dogs were given their first vaccination. Altogether, 50.7% of the dogs had titer greater than or equal to 1:10 to CPV, and 26.1 and 46.2% had titer greater than or equal to 1:8 to CAV-1 and CDV, respectively. The concentration of maternal antibody seemed to be of major importance for failure of immunization with use of inactivated CPV vaccine, but not with CAV-1 and CDV vaccination. In dogs less than 12 months old and vaccinated against CPV infection with inactivated virus, only 11.5% had titer greater than or equal to 1:80. In dogs vaccinated against infectious canine hepatitis and canine distemper, 63.2 and 78.3%, respectively, had titer greater than or equal to 1:16. In adult dogs greater than 2 months old and vaccinated against CPV infection, less than 50% had titer greater than or equal to 1:80, regardless of time after vaccination. There was no significant difference in titer between vaccinated and nonvaccinated dogs.(ABSTRACT TRUNCATED AT 250 WORDS)  相似文献   

2.
Nine puppies without maternal antibody to canine adenovirus (CAV) were divided into two groups. The first consisted of six puppies, each of which was given two doses of a commercial inactivated CAV-1 vaccine, 14 days apart. Eight days after administration of the second dose of vaccine, all six puppies, together with the second group, consisting of three unvaccinated controls, were challenged with an aerosol of virulent CAV-2. One dog from each group was killed on the third, fifth and 10th days after challenge and the three additional vaccinates killed at intervening times. All of the dogs developed respiratory signs, mainly coughing and tachypnoea, but the vaccinated dogs made a more rapid recovery. The lungs of both groups were consolidated, the areas affected being more extensive in the controls, and histological examination revealed the main lesion to be a severe necrotising bronchiolitis. Virus was isolated from the respiratory tissues and from throat swabs collected from both groups of dogs. The presence of neutralising antibody in the serum was not, of itself, sufficient to control viral replication and oblate the disease.  相似文献   

3.
为建立一种简便、快速、高效的可同时区分犬腺病毒1型（canine adenovirus type 1,CAV-1）、犬腺病毒2型（canine adenovirus type 2,CAV-2）、犬冠状病毒（canine coronavirus,CCV）、犬瘟热病毒（canine distemper virus,CDV）、犬细小病毒（canine parvovirus,CPV） 5种常见犬腹泻病毒的基因芯片诊断方法,本研究以CAV-1、CAV-2、CCV、CDV、CPV 5种犬腹泻病毒为靶病毒,根据NCBI上收录的病毒基因序列在其保守区域内设计引物,在此基础上根据变异区域设计针对每种病毒的探针2~3条,优化检测体系的各反应条件,确定该检测方法的特异性与敏感性,建立可同时区分5种病毒的基因芯片检测方法。结果显示,建立的基因芯片检测方法可同时检测以上述5种犬腹泻病毒,其中PCR的退火温度为55℃、延伸时间为1 min 15 s;探针与PCR产物的杂交温度40℃、杂交时间2.5 h时,该方法对CAV-1、CAV-2、CCV、CDV和CPV 5种病毒标准品的检测限分别为0.2 fg/μL、2 fg/μL、2 fg/μL、20 pg/μL和0.02 fg/μL,具有较高的灵敏性;同时对犬副流感病毒进行特异性试验,发现无阳性信号出现,具有较强的特异性;对14份临床腹泻样品检测结果显示,基因芯片方法对CAV-1、CAV-2、CCV、CDV和CPV 5种病毒的阳性检出率分别为28.57%、50.00%、64.28%、14.28%和85.71%,并且基因芯片检测方法的敏感性较PCR要高10~100倍。以上结果表明,本研究建立的基因芯片检测方法具有特异、敏感等特点,对临床中犬类混合感染病毒检测具有一定的诊断意义。  相似文献   

4.
A challenge-of-immunity study was conducted to demonstrate immunity in dogs 3 years after their second vaccination with a new multivalent, modified-live vaccine containing canine adenovirus type 2 (CAV-2), canine parvovirus (CPV), and canine distemper virus (CDV). Twenty-three seronegative pups were vaccinated at 7 and 11 weeks of age. Eighteen seronegative pups, randomized into groups of six dogs, served as challenge controls. Dogs were kept in strict isolation for 3 years following the vaccination and then challenged sequentially with virulent canine adenovirus type 1 (CAV-1), CPV, and CDV. For each viral challenge, a separate group of six control dogs was also challenged. Clinical signs of CAV-1, CPV, and CDV infections were prevented in 100% of vaccinated dogs, demonstrating that the multivalent, modified-live test vaccine provided protection against virulent CAV-1, CPV, and CDV challenge in dogs 7 weeks of age or older for a minimum of 3 years following second vaccination.  相似文献   

5.
A group of client-owned dogs and a group of dogs at a commercial kennel were evaluated for duration of antibody responses against canine parvovirus type 2 (CPV-2) and canine adenovirus type 1 (CAV-1) after receiving a combination vaccine containing recombinant canarypox-vectored canine distemper virus (CDV) and modified-live CPV-2, CAV-2, and canine parainfluenza virus, with (C6) or without (C4) two serovars of Leptospira (Recombitek C4 or C6, Merial). Duration of antibody, which correlates with protective immunity, was found to be at least 36 months in both groups. Recombitek combination vaccines can confidently be given every 3 years with assurance of protection in immunocompetent dogs against CPV-2 and CAV-1 as well as CDV. This allows this combination vaccine, like other, similar modified- live virus combination products containing CDV, CAV-2, and CPV-2, to be administered in accordance with the recommendations of the American Animal Hospital Association Canine Vaccine Task Force.  相似文献   

6.
Serum antibody titers for canine parvovirus type-2 (CPV-2), canine distemper virus (CDV) and canine adenovirus type-1 (CAV-1) were investigated in 1031 healthy adult household dogs (2 to 18 years old) given an annual inoculation in the previous 11 to 13 months. The number of dogs retaining significant titers of antibodies against CPV-2, CDV, and CAV-1 were 888 (86%), 744 (72%), and 732 (71%), respectively. There were no differences between males and females in antibody titers against the 3 viruses. Antibody titer for CPV-2 was significantly higher in younger dogs than in older dogs, CDV antibody was significantly higher in older dogs than in younger dogs, and CAV titer was not associated with age.  相似文献   

7.
  相似文献   

8.
Thirty-two seronegative pups were vaccinated at 8 weeks of age with modified-live canine distemper virus (CDV), canine adenovirus type-2 (CAV-2), and canine parvovirus (CPV) vaccine and at 12 weeks with a modified-live CDV, CAV-2, CPV, and killed rabies virus vaccine. An additional 31 seronegative pups served as age-matched, nonvaccinated controls. All test dogs were strictly isolated for 3 years after receiving the second vaccination and then were challenged with virulent rabies virus. Clinical signs of rabies were prevented in 28 (88%) of the 32 vaccinated dogs. In contrast, 97% (30 of 31) of the control dogs died of rabies infection. These study results indicated that no immunogenic interference occurred between the modified-live vaccine components and the killed rabies virus component. Furthermore, these results indicated that the rabies component in the test vaccine provided protection against virulent rabies challenge in dogs 12 weeks of age or older for a minimum of 3 years following vaccination.  相似文献   

9.
An RT-nPCR assay was used for testing fecal samples of dogs, foxes, raccoon dogs and minks for the presence of canine coronavirus (CCV). The animals were raised in homes, dog schools or farms. Seventy out of 81 healthy dog feces from three cities and 21 out of 48 diarrhea feces from pet dogs were positive for type II CCV. From a total of 61 healthy fox feces, 43 were positive for type II and 29 for type I CCV, out of which 25 were simultaneously positive for the two different genotypes. Among 24 raccoon dogs samples, 22 were CCV type II-positive, and from those 16 were additionally type I positive. No CCVs was detected from healthy mink feces. Sequence analysis found that ten type II CCVs fragments of M gene shared a high similarity with reference strain CCV 1-71 (96.5-99.5%), and four type I CCVs shared a high similarity (96.7%-98.1%) with a reported FCV-like CCV strain. The sequence of one particular M gene fragment was found to cluster between the type I and type II CCV branches in phylogenetic analysis, suggesting the existence of a novel strain. Our study confirmed that type II CCVs infection is very common in domestic dog, fox, and raccoon dog populations in China. This is also the first report on the co-existence of two CCV genotypes in healthy foxes and raccoon dogs.  相似文献   

10.
In order to determine if canine coronavirus (CCV) could be transmitted to pigs, two dogs were inoculated orally with virulent CCV. After 24 h, the dogs were moved to an isolation room that contained three three-day-old pigs. A wire mesh fence, allowing close contact between the animals, separated the dogs from the pigs. The dogs and pigs were observed for 14 days for clinical signs of disease. Samples of blood were obtained from dogs and pigs immediately before the dogs were inoculated with virus and 14 and 28 days later. The dogs developed mild clinical signs of an infection, but the pigs remained normal throughout the observation period. The dogs shed CCV for eight days after exposure. All three pigs developed neutralizing antibodies against CCV and transmissible gastroenteritis virus by 14 days after they were exposed to the dogs.  相似文献   

11.
Two methods of enzyme-linked immunosorbent assay (ELISA) were developed for the diagnosis of canine coronavirus (CCV) infection in dogs. One ELISA, in which CCV-infected CRFK cell lysate is used as antigen, is for the detection and titration of antibody against CCV, and the other ELISA uses the double antibody sandwich method for the detection of CCV antigen. The first ELISA procedure demonstrated antibody responses in dogs inoculated with CCV, as did the virus neutralization test; the second ELISA detected specific CCV antigen in feces and organ homogenates of inoculated dogs.  相似文献   

12.
In our studies aimed at assessing the minimum duration of vaccinal immunity (DOI), approximately 1000 dogs have been vaccinated with products from all the major US veterinary biological companies. The DOI for the various products is determined by antibody titers for all dogs and, by challenge studies in selected groups of dogs. Recently, all major companies that make canine vaccines for the U.S. market have completed their own studies; published data show a 3 years or longer minimum DOI for the canine core products, canine distemper virus (CDV), canine parvovirus type 2 (CPV-2), and canine adenovirus-2 (CAV-2). Studies with feline core vaccines - feline parvovirus (FPV), calicivirus (FCV) and herpes virus type I (FHV-1) have shown a minimum DOI of greater than 3 years. Based on these results, the current canine and feline guidelines (which recommend that the last dose of core vaccines be given to puppies and kittens > or =12 weeks of age or older, then revaccination again at 1 year, then not more often than every 3 years) should provide a level of protection equal to that achieved by annual revaccination. In contrast, the non-core canine and feline vaccines, perhaps with the exception of feline leukaemia vaccines, provide immunity for < or =1 year. In general the effectiveness of the non-core products is less than the core products. Thus, when required, non-core vaccines should be administered yearly, or even more frequently.  相似文献   

13.
Four litters of puppies were divided into three groups. One group was vaccinated with a live CAV-1 vaccine and another with a live CAV-2 vaccine. Throat swabs were collected from two dogs in each of these groups to monitor the possible excretion of vaccine virus, but none was found. Both groups, together with the third group of unvaccinated controls, were challenged 17 days later with an aerosol of virulent CAV-2. One dog from each group was killed on the third, fourth, seventh, ninth, 11th and 14th days after challenge. The unvaccinated dogs developed a clinical disease characterised by anorexia, dullness, coughing and tachypnoea. The lungs were consolidated and histological examination revealed the main lesion to be a severe necrotising bronchiolitis. Large amounts of virus were present in the respiratory tissues of these dogs and high titres of virus were isolated from throat swabs. In contrast, both groups of vaccinated dogs remained clinically almost normal with minimal lesions, present for a much shorter period of time. Virus was found on day 4 in the respiratory tissues of one dog vaccinated with CAV-1 but the other vaccinated animals contained little or no virus. In general, the degree of protection afforded by CAV-1 vaccine seemed similar to that provided by CAV-2 vaccine.  相似文献   

14.
ELISA法检测犬腹泻粪样中的犬冠状病毒   总被引：2，自引：0，他引：2  
用ＦＥ细胞增殖犬冠状病毒（ＣＣＶ）参考株，分别免疫家兔和ＢＡＬＢ／ｃ小鼠制备ＣＣＶ多抗和单抗，建立了夹心ＥＬＩＳＡ及Ｄｏｔ－ＥＬＩＳＡ诊断方法。在检测的８４例犬腹泻粪样中，多抗、单抗夹心法显示ＣＣＶ阳性１６例，Ｄｏｔ－ＥＬＩＳＡ阳性１３例，后１３例包括在前１６例中。从８４例腹泻犬粪样中随机取３８例作ＣＣＶ、犬细小病毒（ＣＰＶ）双项检测，ＣＣＶ阳性１６例，ＣＰＶ阳性６例，ＣＣＶ、ＣＰＶ混合感染４例。结果显示，在南京地区流行的犬腹泻中，ＣＣＶ感染比例有超过ＣＰＶ的趋势。  相似文献   

15.
应用纯化后的犬冠状病毒 (CCV)YS1株细胞培养致弱的弱毒 (CCVYS1V60 ) ,经口鼻和肌肉接种CCV ,SN抗体小于 1∶2的易感犬作安全试验 ,结果未见任何CCV临床症状与病理解剖学改变 ;用不同剂量的该CCV弱毒分组免疫CCV易感犬 ,经SN抗体测定与用CCV强毒攻毒试验 ,结果SN抗体达 1∶60以上的犬 90 %以上可获得免疫保护 ;应用该CCV弱毒分别免疫母源抗体达 1∶4和 1∶8的 2组试验犬 ,第 1次免疫 1 4d后SN抗体均未见升高 ,追加 2～ 3次免疫后 ,SN抗体才逐渐上升至 1∶60以上的免疫保护水平 ;用CCV易感犬和猫肾传代细胞 (CRFK)分别将该CCV细胞培养弱毒连续传 5代和 2 0代 ,结果对犬仍然安全 ,免疫原性也未见下降 ;与犬瘟热病毒 (CDV)、犬传染性肝炎病毒 (ICHV)和犬细小病毒(CPV)弱毒作免疫互扰试验 ,结果与各弱毒的单独免疫结果未见差异 ;该毒的免疫期在 1年以上 ,- 2 0℃冻结保存的保存期为 9个月。  相似文献   

16.
To determine the prevalence of antibodies to four major canine viruses, serum samples were obtained from 190 dogs presented to the Small Animal Hospital at the University of Liverpool. Antibodies to canine coronavirus (CCV), canine distemper virus (CDV), canine parvovirus (CPV) and rotavirus (RV) were assayed using serum neutralisation (CCV and CDV), haemagglutina-tion inhibition (CPV) and indirect fluorescent antibody (RV) techniques. Overall 54 per cent of dogs were seropositive to CCV, 84 per cent to CDV, 70 per cent to CPV and 86 per cent to RV, The antibody titres obtained were analysed with respect to a number of different parameters including: age, sex, breed, vaccination status, exercise regime, diet, Liverpool district in which the dog resided and the presence of diarrhoea, The prevalence and titres of antibodies to CCV, CDV and RV appeared to be influenced by age, CDV by vaccination status, and CCV by the presence of diarrhoea; no other influencing parameters were found.  相似文献   

17.
犬冠状病毒病的免疫预防研究进展   总被引：1，自引：0，他引：1  
犬冠状病毒病是由犬冠状病毒引起的以胃肠炎为主的一种高度接触性传染病,对幼犬危害尤其严重,发病率和死亡率都很高,是目前对养犬业危害较大的疾病之一.文章就犬冠状病毒感染的流行病学、发病机理、机体免疫、免疫程序和免疫预防进行了综述,特别是对犬冠状病毒病的免疫类型、疫苗种类以及免疫预防存在的问题进行了详细阐述.  相似文献   

18.
Twenty-four Beagle pups with high levels of maternal antibody to canine adenovirus type 1 (CAV-1) and canine adenovirus type 2 (CAV-2) were oronasally inoculated with CAV-2 at 4 weeks of age. The CAV-2 was isolated from pharyngeal swabs on postinoculation days 2 through 6. In spite of the infection, maternal antibody continued to decrease for 4 to 8 postinoculation weeks, and then homologous CAV-2 neutralizing antibody and, to a lesser extent, CAV-1 neutralizing antibody began to increase. When these pups were challenge inoculated with CAV-1 and CAV-2 at a time when maternal antibody to CAV-1 would normally have disappeared, they were immune. In addition, 3 pups with maternal antibody to CAV-1 and CAV-2 were intramuscularly inoculated with CAV-2 at 3 weeks of age. Virus was not isolated from these pups, and maternal antibody decreased at a normal rate. These pups were not immune to challenge inoculation with CAV-1 and CAV-2.  相似文献   

19.
OBJECTIVE: To determine serum antibody titers against canine distemper virus (CDV), canine adenovirus type II (CAV-2), and canine parvovirus (CPV) in trained sled dogs prior to and after completion of a long-distance race. DESIGN: Prospective cohort study. ANIMALS: 195 Alaskan sled dogs (from 18 kennels) that participated in the 2006 Iditarod Trail Race. PROCEDURES: All 1,323 dogs participating in the race had been vaccinated against the 3 viruses at 19 to 286 days prior to initial blood sample collection (obtained within the month preceding the race). Within 12 hours of race completion, blood samples were collected from 195 dogs (convenience sample) and matched with each dog's prerace sample. Serum antibody titers (90% confidence intervals [CIs]) were determined via serum neutralization assays. RESULTS: After racing, geometric mean titers against CDV and CPV were significantly higher (2,495 [90% CI, 321 to 16,384] and 6,323 [90% CI, 512 to 32,768], respectively) than prerace values (82 [90% CI, 11 to 362] and 166 [90% CI, 32 to 1,024], respectively). Sixty-one of 194 (31.4%) dogs had > or = 4-fold increases in anti-CPV antibody titers after racing. Prerace serum antibody titers against CDV, CPV, and CAV-2 varied significantly by sled team but were not associated with time since vaccination. CONCLUSIONS AND CLINICAL RELEVANCE: Postrace increases in serum anti-CDV and anti-CPV antibody titer might reflect exposure of dogs to these agents immediately before or during racing. Dogs had no clinical signs of CDV-, CAV-2-, or CPV-associated disease; therefore, the clinical importance of these titer changes is uncertain.  相似文献   

20.
AIM: To report on the isolation and identification of canine adenovirus type-2 (CAV-2) from a greyhound dog with tracheitis/tonsillitis. METHODS: Virus isolation was performed with Madin and Darby canine kidney (MDCK) cell monolayers using standard virological techniques. The isolated virus was identified by haemagglutination inhibition and serum neutralisation tests. Viral DNA was extracted from infected MDCK cells and subjected to restriction endonuclease analysis using the endonuclease enzymes Bam HI, Bgl II, Eco RI and Hind III. RESULTS: A virus, designated 5 113-87, was isolated in MDCK cells yielding typical cytopathic effect. The virus could be neutralised with a CAV-2 specific reference antiserum and also showed some cross neutralisation with CAV-1 specific reference antiserum. The virus 5 113-87 had a high haemagglutination inhibition titre with CAV-2 antiserum using human group 0 red blood-cells and CAV-1 and CAV-2 reference antisera. This virus also had DNA restriction profiles identical to those of the reference CAV-2 (Toronto A26/61), whereas previously isolated strains of adenovirus from dogs in New Zealand had DNA restriction patterns identical to the prototype CAV-1 strain (Utrecht). CONCLUSION: The findings show that the virus 5 113-87 isolated from the upper respiratory tract of a dog in New Zealand is CAV-2.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号